EMCURE.NS
Cash Flow
Emcure Pharmaceuticals Ltd. · Healthcare
Cash Flow · 2 years on file
(FY2024-25 to FY2025-26)
· fetched 2026-09-23 02:12
| Line item | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|
| Net Cash from Operating Activities | ₹851.71 Cr. | ₹943.54 Cr. | CashFlowsFromUsedInOperatingActivities |
| Net Cash from Investing Activities | ₹-94.00 Cr. | ₹-1,193.06 Cr. | CashFlowsFromUsedInInvestingActivities |
| Net Cash from Financing Activities | ₹-813.96 Cr. | ₹343.43 Cr. | CashFlowsFromUsedInFinancingActivities |
| Effect of Exchange Rate Changes | ₹-2.05 Cr. | ₹18.16 Cr. | EffectOfExchangeRateChangesOnCashAndCashEquivalents |
| Net Increase/(Decrease) in Cash | ₹-58.30 Cr. | ₹112.08 Cr. | IncreaseDecreaseInCashAndCashEquivalents |
| Cash and Cash Equivalents (Closing) | N/A | N/A | CashAndCashEquivalentsCashFlowStatement |
| Dividends Paid | ₹0.00 Cr. | ₹56.85 Cr. | DividendsPaidClassifiedAsFinancingActivities |
Every figure above is the exact value of the named XBRL element from EMCURE.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).